PE/Cyanine7 anti-human CD45RA Antibody
- 产品名称：
- PE/Cyanine7 anti-human CD45RA Antibody
- 产品类别：
- 抗体
- 产品编号：
- 304125
- 产品应用：
- 304125
[价格]
| 规格 |
价格 |
库存 |
| 25tests |
￥ 1524 |
1 |
- Verified Reactivity
- Human
- Reported Reactivity
- Chimpanzee
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
- Preparation
- The antibody was purified by affinity chromatography and conjugated with PE/Cyanine7 under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.
- Excitation Laser
- Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
- Application Notes
Additional reported applications (for relevant formats of this clone) include: inhibition of CD45 functions2, immunohistochemical staining of frozen tissue sections3 and formalin-fixed paraffin-embedded tissue sections4, and immunocytochemistry15,16.
- Additional Product Notes
- BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
- Application References
(PubMed link indicates BioLegend citation) -
- Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
- Yamada T, et al. 2002. J. Biol. Chem. 277:28830. (WB, Block)
- Weninger W, et al. 2003 J. Immunol. 170:4638. (IHC-F)
- Imanguli MM, et al. 2009. Blood. 113:3620 (IHC-P)
- Roque S, et al. 2007. J. Immunol. 178:8028. (FC) PubMed
- Smeltz RB. 2007. J. Immunol. 178:4786. (FC) PubMed
- Palendira U, et al. 2008. Blood (FC) PubMed
- Kuttruff S, et al. 2009. Blood 113:358. (FC) PubMed
- Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
- Alanio C, et al. 2010. Blood 115:3718. (FC) PubMed
- Iannello A, et al. 2010. J. Immunol. 184:114. (FC) PubMed
- Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- Guereau-de-Arellan M, et al. 2011. Brain. 134:3578. PubMed
- Canque B, et al. 2000. Blood 96:3748. (ICC)
- Imanguli MM, et al. 2009. Blood 13:3620. (ICC)
- Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
- Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
- Product Citations
-
- Robinson GA, et al. 2021. EBioMedicine. 103243:. PubMed
- Jiang XL, et al. 2021. Nat Commun. 12:897. PubMed
- Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed
- Andonian BJ, et al. 2022. Sci Rep. 12:7450. PubMed
- Braun J, et al. 2020. Nature. 587:270. PubMed
- Zhou R, et al. 2020. Immunity. S1074-7613(20)30333-2.. PubMed
- Koido S, et al. 2014. Clin Cancer Res. 20:4228. PubMed
- Schulthess J et al. 2019. Immunity. 50(2):432-445 . PubMed
- Hinderer S, et al. 2012. Biomaterials. 33:5259. PubMed
- Ollé Hurtado M, et al. 2019. PLoS One. 14:e0216373. PubMed
- Schilling B, et al. 2014. Ann Oncol. 25:747. PubMed
- Tatovic D, et al. 2015. J Immunol. 195: 386 - 392. PubMed
- Rubio-Pérez C, et al. 2021. Nat Commun. 1503:12. PubMed
- Presicce P, et al. 2011. PLoS One. 6:e28118. PubMed
- B?iers C, et al. 2018. Dev Cell. 44:362. PubMed
- Basar R, et al. 2021. Cell Reports. 36(3):109432. PubMed
- H?nes J, et al. 2017. Sci Rep. . 10.1038/s41598-017-15866-9. PubMed
- Basar R, et al. 2020. bioRxiv. . PubMed
- Braza F, et al. 2015. J Am Soc Nephrol. 26: 1795-1805. PubMed
- Zhu Y, et al. 2019. Cell Stem Cell. 25:542. PubMed
- Serwas NK, et al. 2019. Nat Commun. 2.573611111. PubMed
- Yang L, et al. 2020. Genes Dis. 7:128. PubMed
- Prado-Garcia H, et al. 2017. Cancer Immunol Immunother. 10.1007/s00262-017-1979-x. PubMed
- Hunter S, et al. 2018. J Hepatol. 69:654. PubMed
- Bourges C, et al. 2020. EMBO Mol Med. 12:e12112. PubMed
- Imura Y, et al. 2020. JCI Insight. :5. PubMed
- Gorman JA, et al. 2019. Front Immunol. 10:44. PubMed
- Mathiasen SL, et al. 2021. Cell Reports. 35(10):109220. PubMed
- Li W, et al. 2020. Immunity. 53(2):456-470. PubMed
- Roy S, et al. 2021. Nat Commun. 12:3182. PubMed
- Luetke-Eversloh M, et al. 2014. PLoS Pathog. 10:1004441. PubMed
- Collinson–Pautz MR, et al. 2019. Leukemia. 33:2195. PubMed
- Pierini S, et al. 2020. JCI Insight. 5:00. PubMed
- Kelly DL, et al. 2018. Psychiatry Res. 269:517. PubMed
- Salumets A, et al. 2022. Aging Cell. 21:e13607. PubMed
- Sharei A, et al. 2015. PLoS One. 10:118803. PubMed
- Abdel-Mohsen M, et al. 2016. PLoS Pathog. 12: 1005677. PubMed
- Gamradt S, et al. 2021. iScience. 24:103312. PubMed
- Sananez I, et al. 2021. EBioMedicine. 72:103615. PubMed
- RRID
- AB_10709440 (BioLegend Cat. No. 304125) AB_10708879 (BioLegend Cat. No. 304126)
- Structure
- Tyrosine phosphatases, type I transmembrane (exon 4 splicing of CD45 gene), 205-220 kD
- Distribution
-
B cells, na?ve T cells, monocytes
- Function
- Enhances TCR and BCR signaling
- Ligand/Receptor
- Galectin-1, CD2, CD3, CD4
- Cell Type
- B cells, Monocytes, T cells, Tregs
- Biology Area
- Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
- Molecular Family
- CD Molecules
- Antigen References
-
1. Thomas M. 1989. Annu. Rev. Immunol. 7:339.
2. Trowbridge I, et al. 1994. Annu. Rev. Immunol.12:85.
- Gene ID
- 5788 View all products for this Gene ID
- UniProt
- View information about CD45RA on UniProt.org
